Abstract
In recent years low-dose methotrexate (MTX) therapy was shown to be effective in the treatment of collagen diseases, including polymyositis (PM).1 Pulmonary toxicity has been estimated to occur in 7.6% to 33% of patients receiving high doses of MTX, but it appears to be rare in patients receiving low-dose MTX therapy. Cooper et al2 reported that MTX-induced pneumonitis has since been found in 5% to 7% of MTX-treated patients. Although
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
